Ionis and AstraZeneca close deal to develop and commercialize eplontersen

CARLSBAD, Calif., Dec. 29, 2021 -- (Healthcare Sales & Marketing Network) -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapies, today announced the closing of the collaboration agreement with AstraZeneca to develop and comme... Biopharmaceuticals Ionis Pharmaceuticals, AstraZeneca, eplontersen, transthyretin amyloidosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news